To the content
2 . 2020

Alternative variants of interleukin-2 receptor alpha chain mRNA in colon cancer


Introduction. The alpha chain of the interleukin-2 receptor is encoded by a full-length mRNA which has several alternatively spliced variants whose function is unknown. Information on the occurrence of alternatives to mRNA alpha chain IL-2R in colon cancer help establish their role in antitumor immunity mechanisms.

The aim of the study was to detect the content of soluble CD25 molecules, a full-length form of IL-2Rα mRNA (CD25 mRNA) encoding a functionally active receptor alpha-chain and a form with 4 exon deletion (CD25Exo4Del mRNA) and 4 and 5 exons deletion (CD25Exo4-5Del mRNA) encoding a protein unable to bind interleukin-2. In the blood of healthy individuals and in the blood and tumors of colon cancer patients and compare the expression of IL-2Rα mRNA alternative forms with an expression of the genes coding CD38, ICAM-1, Fas and several cancer-testicular antigens (MAGEA1-MAGEA6, CT7 (MAGEC1), GAGE1-GAGE8, NY-ESO-1, SSX1, 2, 4, TRAG3 and XAGE1) expression.

Material and methods. 49 tumor samples and 10 peripheral blood samles of colon cancer are used in the work. The study was carried out by a reverse transcription polymerase chain reaction.

Results. It was shown that three alternative forms of mRNA IL-2Rα present in the blood of both healthy individuals and patients with colon cancer. In tumors, alternative mRNAs of IL-2Rα were detected with different frequencies. Full-length mRNA was detected most often, CD25Exo4Del mRNA - with an intermediate frequency and CD25Exo4-5Del mRNA - most rarely. There was a tendency to decrease the frequency of CD25Exo4-5Del mRNA detection in the late stages of the disease. ICAM-1 expression frequency in mRNA CD25Exo4-5Del negative tumors was increased, and soluble CD25 molecules serum level in the absence of CD25Exo4Del mRNA in tumor was also increased.

Сonclusion. The regulatory role of IL-2Rα mRNA deleted forms products leading to regulatory T cells activation, immunosuppression increasing and tumor growth progression was established.

Keywords:interleukin-2 receptor alpha-chain; mRNA alternative variants; colon cancer; regulatory T cells

For citation: Novikov V.V., Shumilova S.V, Novikov D.V, Alyasova A.V, Evsegneeva I.V., Karaulov A.V. Alternative variants of interleukin-2 receptor alpha chain mRNA in colon cancer. Immunologiya. 2019; 41 (2): 144-53. DOI: 10.33029/0206-4952-2020-41-2-144-153 (in Russian)

Funding. The study had no sponsor support.

Conflict of interests. The authors declare no conflict of interests.


1. Kuhn D.J., Dou Q.P. The role of interleukin-2 receptor alpha in cancer. Front. Biosci. 2005; 10: 1462–74. DOI: 10.2741/1631.

2. Cosman D. Cloning, sequence and expression of human interleukin-2 receptor. Nature. 1984; 312 (5996): 768–71. DOI: 10.1038/312768a0.

3. Castrignano T., D’Antonio M., Anselmo A. Carrabino D., et al. ASPicDB: a databaseresource for alternative splicing analysis. Bioinformatics. 2008; 24 (10): 1300–4. DOI: 10.1093/bioinformatics/btn113.

4. Ishida N., Kanamori H., Noma T., Nikaido T., et al. Molecular cloning and structure of the human interleukin 2 receptor gene. Nucleic Acids Res. 1985; 13 (21): 7579–89. DOI: 10.1093/nar/13.21.7579.

5. Novikova S.V. (Schumilova S.V.), Alyasova A.V., Novikov D.V. Development and testing of the method of detection of alpha-chain mRNA of interleukin-2 receptor in cells of human tumors. Vestnik Nizhegorodskogo universiteta im. N.I. Lobachevskogo. 2010; 2 (2): 563–65. (in Russian)

6. Kubysheva N., Postnikova L., Soodaeva S., Novikov V., et al. Relationship of the content of systemic and endobronchial soluble molecules of CD25, CD38, CD8, and HLA-I-CD8 and Lung function parameters in COPD patients. Dis. Markers. 2017. Vol. 2017. DOI:10.1155/2017/8216723.

7. Novikov V.V., Egorova N.I., Kurnikov G.Yu., Evsegneeva I.V. The Serum level of soluble HLA molecules and IL-2R at urogenital chlamydial infection. Adv. Exp. Med. Biol. 2007; 601: 285–89.

8. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162 (1): 156–59. DOI: 10.1006/abio.1987.9999.

9. Novikov V.V., Evsegneeva I.V. New human differentiation antigens approved at the VII International Vorkshop. Rossiyskiy bioterapevticheskiy zhurnal. 2003; 2 (3): 3–6. (in Russian)

10. Golyshko P.V., Novikov D.V., Ananiev S.V., Baryshnikov K.A., et al. Cancer-testicular genes in patients with colorectal cancer. Rossiyskiy bioterapevticheskiy zhurnal. 2015; 1: 19–25. (in Russian)

11. Novikov D.V., Belova T.V., Pegov R.G., Alyasova A.V., et al. The frequency of mRNA detection is MAGE-А1-А6 in the blood of oncological patients. Klinicheskaya laboratornaya diagnostika. 2009; 4: 25–7. (in Russian)

12. Choi C. Homo sapiens interleukin-2 receptor mRNA, alternatively spliced, partial CDS. In: Submitted Neurology. Shinchon-dong, South Korea : Yonsei University, 1997. URL:

13. Nagata S., Golstein P. The Fas death factor. Science. 1995; 267: 1449–56. DOI: 10.1126/science.7533326.

14. Deaglio S., Mehta K., Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 2001; 25 (1): 1–12. DOI: 10.1016/s0145-2126(00)00093-x.

15. Wingren A.G., Parra E., Varga M., Kalland T. T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit. Rev. Immunol. 2017; 37 (2-6): 463–81. DOI: 10.1615/critrevimmunol.v15.i3-4.30

16. Perenkov A.D., Novikov D.V., Sakharnov N.A., et al. Heterogeneous CD38 expression in tumor tissues of patients with colorectal cancer. Mol. Biol. 2012; 46 (5): 705–9.

17. Novikov D.V., Fomina S.G., Gurina N.N., Perenkov A.D., et al. Correlation of expression of MUC1, ICAM1, IL32, FcγR3A and FoxP3 in tumor centers of breast cancer patients. Klinicheskaya laboratornaya diagnostika. 2017; 1: 37–41. (in Russian)

18. Golenkov A.K., Mitina T.A., Novikov V.V., et al. Clinical significance of soluble adhesion molecules (sCD50-ICAM-3), apoptosis (sCD95) and class I sHLA in lymphoproliferative diseases. Rossiyskiy bioterapevticheskiy zhurnal. 2002; 1 (1): 60–4. (in Russian)

19. Utkin O.V., Svintsova T.A., Kravchenko G.A., Shmeleva O.A., et al. Expression of alternative forms of gene CD95/FAS in blood cells at herpesviral infection. Immunologiya. 2012; 33 (4): 189–93. (in Russian)

20. Wang Q., Li B., Liu B., Liu Y.B., et al. Polymorphisms of the ICAM-1 exon 6 (E469K) are associated with differentiation of colorectal cancer. J. Exp. Clin. Cancer Res. 2009; 28: 139–45. DOI: 10.1186/1756-9966-28-139.

21. Hamai A., Meslin F., Benhalam H., Jalil A., et al. ICAM-1 has a critical role in the regulation of metastatic melanoma tumor susceptibility to CTL lysis by interfering with PI3K/AKT pathway. Cancer Res. 2008; 68 (23): 9854–64. DOI: 10.1158/0008-5472.CAN-08-0719.

22. Novikov V.V., Karaulov A.V., Baryshnikov A.Y. Soluble forms of membrane antigens of immune system cells. Moscow: Meditsinskoe informatsionnoe agentstvo, 2008: 249 p.

23. García-Tuñón I., Ricote M., Ruiz A., Fraile B., et al. Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study. Breast Cancer Res. 2004; 6 (1): R1–7. DOI: 10.1186/bcr730.

24. Loose D., Signore A., Bonanno E., Vermeersch H., et al. Prognostic value of CD25 expression on lymphocytes and tumor cells in squamous-cell carcinoma of the head and neck. Cancer Biother. Radiopharm. 2008; 23 (1): 25–33. DOI: 10.1089/cbr.2007.0373.

25. McDoniels-Silvers A.L., Stoner G.D., Lubet R.A., You M. Differential expression of critical cellular genes in human lung adenocarcinomas and squamous cell carcinomas in comparison to normal lung tissues. Neoplasia. 2002; 4 (2): 141–50. DOI: 10.1038/sj.neo.7900217.

26. Guoping D. Tumor-infiltrating regulatory T cells: origins and features. Am. J. Exp. Immunol. 2018; 7 (5): 81–7.

27. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 2001; 167 (3): 1245–53. DOI: 10.4049/jimmunol.167.3.1245.